FIELD: biotechnology.
SUBSTANCE: invention relates to a variant protein of the Fc domain of an immunoglobulin, and can be used to extend the half-life of a therapeutically active protein in vivo when a variant protein of the Fc domain of an immunoglobulin is fused to it. A variant immunoglobulin Fc-domain protein is proposed, containing the following SEQ ID NO: 6, 7, 8 or 9, a fusion protein thereto, nucleic acids and expression vectors encoding them, homo- and heterodimers of the fusion protein, as well as a method for increasing the half-life of the therapeutic protein in vivo.
EFFECT: invention makes it possible to obtain proteins based on the immunoglobulin Fc-domain with an extended half-life in vivo and minimized antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) associated with the Fc-region.
11 cl, 39 dwg, 16 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
| PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| COMPOSITION FOR CULTURING REGULATORY T-CELLS AND ITS APPLICATION | 2020 |
|
RU2807802C1 |
